Allyx Therapeutics Awarded $3.3 Million NIH Grant to Support Further Clinical Studies of Lead Candidate ALX-001
15. Oktober 2024 07:05 ET
|
Allyx Therapeutics Inc.
Allyx Therapeutics has been awarded a $3.3 million grant as part of the NIH's Small Business Innovation Research Commercial Readiness Pilot program
SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure
30. April 2024 08:30 ET
|
SeaStar Medical Holding Corporation
DENVER, April 30, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of...
Global Down Syndrome Foundation Applauds House Energy & Commerce Committee for Advancing Legislation to Authorize Down Syndrome Research Program at NIH
12. März 2024 13:30 ET
|
Global Down Syndrome Foundation
Denver, CO, March 12, 2024 (GLOBE NEWSWIRE) -- The Global Down Syndrome Foundation (GLOBAL) praised the House Energy and Commerce Health Subcommittee for approving the DeOndra Dixon INCLUDE Project...
National Institutes of Health Awards Grant to SINTX Technologies for Development of 3D Printed Craniomaxillofacial Devices
10. März 2022 09:00 ET
|
SINTX Technologies, Inc.
SALT LAKE CITY, March 10, 2022 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (www.sintx.com) (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer of advanced ceramics,...
Rendever Receives $2M NIH Phase II Grant to Further Research the Impact of Virtual Reality on the Aging Population
17. August 2021 11:23 ET
|
Rendever
BOSTON, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Rendever, a virtual reality (VR) platform built to help seniors overcome social isolation through shared experiences, today announces that it has been...
Trevena Reports Second Quarter 2021 Results
12. August 2021 07:00 ET
|
Trevena Inc.
Company reaffirms YE goal of 100 formulary wins OLINVYK respiratory physiology study currently enrolling, topline data expected by YE 2021 NIH / Vanderbilt University Medical Center-led...
Trevena Announces First Patient Enrolled in NIH-Funded ACTIV-4 Host Tissue Trial of TRV027 for COVID-19
26. Juli 2021 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., July 26, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces NIH Has Resumed Recruiting Patients in Proof-of-Concept Study for TRV734 in Opioid Use Disorder
16. Juni 2021 07:00 ET
|
Trevena Inc.
-- TRV734 reduced drug-seeking behavior in a preclinical model of relapse, suggesting its utility as a novel oral maintenance treatment for opioid use disorder The study is being conducted and...
February is American Heart Month - Top Tips to Keep Your Ticker in Tip Top Shape By Dr Aimee Harris-Newon
13. Februar 2021 13:19 ET
|
Dr. Aimee Harris-Newon
Bloomingdale, Illinois, Feb. 13, 2021 (GLOBE NEWSWIRE) -- Every February Americans observe American Heart Month to raise awareness and reaffirm the importance of a healthy heart. Heart disease...
Provectus Biopharmaceuticals Announces Presentation of Preliminary Data from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Refractory Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020
17. September 2020 07:00 ET
|
Provectus Biopharmaceuticals Inc.
36% ORR and 64% DCR (RECIST 1.1)PV-10-induced, tumor-specific restoration of T cell functionData compare favorably to approved and investigational therapies for patient population KNOXVILLE, TN,...